Sugi Predict

Sugi Predict / Compounds / SCHEMBL3716602

SCHEMBL3716602

SCHEMBL3716602

Cc1ccc(S(=O)(=O)NC[C@H](C)O)cc1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GBA1 P04062 1/20 0.70
▸ ALDH1A1 P00352 8/20 0.68
▸ TSHR P16473 1/20 0.68
▸ CA2 P00918 6/20 0.53
▸ CA1 P00915 5/20 0.53
▸ MMP1 P03956 1/20 0.53
▸ MMP2 P08253 1/20 0.53
▸ MMP9 P14780 1/20 0.53
▸ MMP8 P22894 1/20 0.53
▸ MMP13 P45452 1/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ CA12 O43570 2/20 0.51
▸ CA9 Q16790 2/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP3A4 P08684 1/20 0.51
▸ ATM Q13315 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ CYP19A1 P11511 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4463262 1.00 GBA1 (0.70) GBA1ALDH1A1TSHRCA2CA1
SCHEMBL3723855 1.00 GBA1 (0.70) GBA1ALDH1A1TSHRCA2CA1
SCHEMBL28686588 0.87 GBA1 (0.67) GBA1ALDH1A1TSHRCA2CA1
P-Toluenesulfonamide SCHEMBL16007442 0.87 GBA1 (0.58) GBA1ALDH1A1TSHRCA2CA1
SCHEMBL6324022 0.86 CA1 (0.51) GBA1ALDH1A1TSHRCA2CA1
SCHEMBL7862567 0.85 GBA1 (0.74) GBA1ALDH1A1TSHRCA2CA1
SCHEMBL6789995 0.84 CA1 (0.57) GBA1ALDH1A1TSHRCA2CA1
SCHEMBL14132568 0.84 CA1 (0.53) GBA1ALDH1A1TSHRCA2CA1
SCHEMBL3412348 0.84 CA1 (0.52) GBA1ALDH1A1TSHRCA2CA1
SCHEMBL6321465 0.84 CA1 (0.52) GBA1ALDH1A1TSHRCA2CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117597333-A Heterocyclic compounds as receptor 2-triggering agonists expressed on myeloid cells and methods of use 维吉尔神经科学股份有限公司 2024-02-23 — — CN disclosed
US-20230321016-A1 COMBINATION THERAPY FOR TREATING CANCER GONGWIN BIOPHARM CO., LTD (TW) 2023-10-12 — — US disclosed
US-11752160-B2 Method for reducing fat by administering benzenesulfonamide compositions GONGWIN BIOPHARM CO., LTD (TW) 2023-09-12 — — US disclosed
US-11752118-B2 Method for treating melanoma GONGWIN BIOPHARM CO., LTD (TW) 2023-09-12 — — US disclosed
US-20220168248-A1 METHOD FOR TREATING MELANOMA GONGWIN BIOPHARM CO., LTD (TW) 2022-06-02 — — US disclosed
US-20200338028-A1 BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR MODULATING LIPID RAFT GONGWIN BIOPHARM CO., LTD. (TW) 2020-10-29 — — US disclosed
US-10548862-B2 Topical formulation and method for preventing or treating acne Wu, Lester J. (US) 2020-02-04 — — US disclosed
US-20190321313-A1 BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR TREATING CANCER Gongwin Biopharm Holdings Co., Ltd. 2019-10-24 — — US disclosed
US-20190201356-A1 TOPICAL FORMULATION AND METHOD FOR PREVENTING OR TREATING ACNE GONGWIN BIOPHARM CO., LTD. (TW) 2019-07-04 — — US disclosed
US-9782370-B2 Pharmaceutical compositions of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma Gongwin Biopharm Holdings Co., Ltd. (KY) 2017-10-10 — — US disclosed
US-20170172951-A1 NOVEL PHARMACEUTICAL COMPOSITIONS OF BENZENESULFONAMIDE DERIVATIVES FOR TREATMENT OF ADENOID CYSTIC CARCINOMA GONGWIN BIOPHARM CO., LTD. (TAIWAN) (TW) 2017-06-22 — — US disclosed
WO-2010136778-A1 DIBENZOTHIOPHENE DERIVATIVES AS DNA- PK INHIBITORS KUDOS PHARMACEUTICALS LIMITED (GB) 2010-12-02 — — WO disclosed
WO-2010136778-A1 DIBENZOTHIOPHENE DERIVATIVES AS DNA- PK INHIBITORS KUDOS PHARMACEUTICALS LIMITED (GB) 2010-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190321313-A1 BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR TREATING CANCER ARSA, ABCB1, ABCG2 GBA1 105/4885ALDH1A1 689/4885TSHR 3434/4885
US-20170172951-A1 NOVEL PHARMACEUTICAL COMPOSITIONS OF BENZENESULFONAMIDE DERIVATIVES FOR TREATMENT OF ADENOID CYSTIC CARCINOMA ABCD3, CFTR, ADSL GBA1 1286/4885ALDH1A1 1243/4885TSHR 3406/4885
US-10548862-B2 Topical formulation and method for preventing or treating acne CUTA, STS, ALAD GBA1 1583/4885ALDH1A1 669/4885TSHR 2402/4885
US-11752160-B2 Method for reducing fat by administering benzenesulfonamide compositions LIPE, FABP4, LIPA GBA1 95/4885ALDH1A1 728/4885TSHR 2439/4885
US-20220168248-A1 METHOD FOR TREATING MELANOMA TYR, MITF, BRAF GBA1 264/4885ALDH1A1 528/4885TSHR 3113/4885
US-20230321016-A1 COMBINATION THERAPY FOR TREATING CANCER TP53, MCL1, TOP2B GBA1 722/4885ALDH1A1 381/4885TSHR 4098/4885
US-11752118-B2 Method for treating melanoma TYR, MITF, BRAF GBA1 264/4885ALDH1A1 528/4885TSHR 3113/4885
US-20200338028-A1 BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR MODULATING LIPID RAFT ABCB4, SPTSSB, SMPD2 GBA1 36/4885ALDH1A1 1604/4885TSHR 3589/4885
US-20190201356-A1 TOPICAL FORMULATION AND METHOD FOR PREVENTING OR TREATING ACNE CUTA, STS, ALAD GBA1 1583/4885ALDH1A1 669/4885TSHR 2402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.